You just read:

European Commission Approves Astellas' XOSPATA™ for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay

News provided by

Invivoscribe, Inc.

Oct 30, 2019, 06:00 ET